Immune-based treatment re-challenge in renal cell carcinoma: A systematic review and meta-analysis.

ABSTRACT:

Introduction

The use of immune checkpoint inhibitors (ICIs) as a front-line treatment for metastatic renal cell carcinoma (RCC) has significantly improved patient' outcome. However, little is known about the efficacy or lack thereof of immunotherapy after prior use of anti-PD1/PD-L1 or/and anti-CTLA monoclonal antibodies.

Methods

Electronic databases, including PubMed, EMBASE, Medline, Web of Science, and Cochrane Library, were comprehensively searched from inception to July 2022. Objective response rates (ORR), progression-free survival (PFS), and ≥ grade 3 adverse events (AEs) were assessed in the meta-analysis, along with corresponding 95% confidence intervals (CIs) and publication bias.

Results

Ten studies which contained a total of 500 patients were included. The

SUBMITTER: Papathanassiou M 

PROVIDER: S-EPMC9756433 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature